{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:24:33Z","timestamp":1784957073656,"version":"3.55.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"published-print":{"date-parts":[[2021,8,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    On 7 June\n                    <jats:sub>,<\/jats:sub>\n                    the FDA approved aducanumab, the first new drug for Alzheimer\u2019s disease in almost 20\u00a0years\u2014and notably, the first drug with a putative disease\u2010modifying mechanism for the treatment of this devastating disorder, namely the removal of \u03b2\u2010amyloid (or A\u03b2) plaques from the brain.\n                  <\/jats:p>","DOI":"10.15252\/emmm.202114781","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T07:45:41Z","timestamp":1627890341000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Aducanumab: a new phase in therapeutic development for Alzheimer\u2019s disease?"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5163-640X","authenticated-orcid":false,"given":"Giovanna","family":"Lalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2059-024X","authenticated-orcid":false,"given":"Jonathan M","family":"Schott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3122-0423","authenticated-orcid":false,"given":"John","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5455-5819","authenticated-orcid":false,"given":"Bart","family":"De Strooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,2]]},"reference":[{"key":"BFEMMM202114781_CR2","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1001\/jama.2021.3854","volume":"325","author":"GC Alexander","year":"2021","unstructured":"Alexander GC, Emerson S, Kesselheim AS (2021) Evaluation of Aducanumab for Alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility. JAMA 325: 1717\u20131718","journal-title":"JAMA"},{"key":"BFEMMM202114781_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2009.10.002","volume":"85","author":"S Broder","year":"2010","unstructured":"Broder S (2010) The development of antiretroviral therapy and its impact on the HIV\u20101\/AIDS pandemic. Antiviral Res 85: 1\u201318","journal-title":"Antiviral Res"},{"key":"BFEMMM202114781_CR3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13195-019-0529-5","volume":"11","author":"J Cummings","year":"2019","unstructured":"Cummings J, Feldman HH, Scheltens P (2019) The \u201crights\u201d of precision drug development for Alzheimer\u2019s disease. Alzheimers Res Ther 11: 76","journal-title":"Alzheimers Res Ther"},{"key":"BFEMMM202114781_CR4","volume":"7","author":"J Cummings","year":"2021","unstructured":"Cummings J, Lee G, Zhong K, Fonseca J, Taghva K (2021) Alzheimer\u2019s disease drug development pipeline: 2021. Alzheimers Dement 7: e12179","journal-title":"Alzheimers Dement"},{"key":"BFEMMM202114781_CR5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","volume":"164","author":"B De Strooper","year":"2016","unstructured":"De Strooper B, Karran E (2016) The cellular phase of Alzheimer's disease. Cell 164: 603\u2013615","journal-title":"Cell"},{"key":"BFEMMM202114781_CR6","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrd3505","volume":"10","author":"E Karran","year":"2011","unstructured":"Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10: 698\u2013712","journal-title":"Nat Rev Drug Discov"},{"key":"BFEMMM202114781_CR7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13195-019-0559-z","volume":"11","author":"G Klein","year":"2019","unstructured":"Klein G, Delmar P, Voyle N, Rehal S, Hofmann C, Abi\u2010Saab D, Andjelkovic M, Ristic S, Wang G, Bateman R et\u00a0al (2019) Gantenerumab reduces amyloid\u2010\u03b2 plaques in patients with prodromal to moderate Alzheimer\u2019s disease: a PET substudy interim analysis. Alzheimers Res Ther 11: 101","journal-title":"Alzheimers Res Ther"},{"key":"BFEMMM202114781_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(21)00197-8","author":"KY Liu","year":"2021","unstructured":"Liu KY, Schneider LS, Howard R (2021) The need to show minimum clinically important differences in Alzheimer\u2019s disease trials. Lancet Psychiatry https:\/\/doi.org\/10.1016\/S2215\u20100366(21)00197\u20108","journal-title":"Lancet Psychiatry"},{"key":"BFEMMM202114781_CR9","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks JD, Sims JR, Brys M et\u00a0al (2021) Donanemab in early Alzheimer\u2019s disease. New Engl J Med 384: 1691\u20131704","journal-title":"New Engl J Med"},{"key":"BFEMMM202114781_CR10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/d41586-021-01546-2","volume":"594","author":"A Mullard","year":"2021","unstructured":"Mullard A (2021) Landmark Alzheimer\u2019s drug approval confounds research community. Nature 594: 309\u2013310","journal-title":"Nature"},{"key":"BFEMMM202114781_CR11","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1126\/science.abk0575","volume":"372","author":"JS Perlmutter","year":"2021","unstructured":"Perlmutter JS (2021) FDA\u2019s green light, science\u2019s red light. Science 372: 1371","journal-title":"Science"},{"key":"BFEMMM202114781_CR12","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","volume":"27","author":"S Salloway","year":"2021","unstructured":"Salloway S, Farlow M, McDade E, Clifford DB, Wang G, Llibre\u2010Guerra JJ, Hitchcock JM, Mills SL, Santacruz AM, Aschenbrenner AJ et\u00a0al (2021) A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease. Nat Med 27: 1187\u20131196","journal-title":"Nat Med"},{"key":"BFEMMM202114781_CR13","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chetelat G, Teunissen CE, Cummings J, van der Flier WM (2021) Alzheimer\u2019s disease. Lancet 397: 1577\u20131590","journal-title":"Lancet"},{"key":"BFEMMM202114781_CR14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A et\u00a0al (2021) A randomized, double\u2010blind., phase 2b proof\u2010of\u2010concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti\u2010A\u03b2 protofibril antibody. Alzheimers Res Ther 13: 80","journal-title":"Alzheimers Res Ther"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/emmm.202114781.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.15252\/emmm.202114781","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.15252\/emmm.202114781\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.embopress.org\/doi\/pdf\/10.15252\/emmm.202114781","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/emmm.202114781.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:35:11Z","timestamp":1779086111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.15252\/emmm.202114781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,2]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8,9]]}},"alternative-id":["BFEMMM202114781"],"URL":"https:\/\/doi.org\/10.15252\/emmm.202114781","relation":{},"ISSN":["1757-4676","1757-4684"],"issn-type":[{"value":"1757-4676","type":"print"},{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,2]]},"assertion":[{"value":"28 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GL has no competing interests. JMS has consulted for Biogen and was a member of the EMERGE and ENGAGE Interpretation Task Force. He is Chief Medical Officer of Alzheimer\u2019s Research UK and Medical Advisor to the UK Dementia Research Institute. Views expressed here do not necessarily reflect those of these organizations. JH is an occasional consultant for Eisai on their microglial programme and an advisor for Eli Lilly on their amyloid programme. BDS is consultant for Eisai, ReMYND NV, AbbVie and Muna\u2010K5. He is the scientific founder of Augustine TX and Muna\u2010K5 and has a small amount of shares from Muna\u2010K5. He is director of the UK Dementia Research Institute. The commentary reflects his personal views. BDS is a senior academic editor of\n                      EMBO Molecular Medicine\n                      .","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"EMMM202114781"}}